Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2975

  • Filters activated: Toxicology. Clear all to show 5105 items.
1.

Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.

Xu J, Lv TT, Zhou XF, Huang Y, Liu DD, Yuan GL.

Medicine (Baltimore). 2018 Sep;97(39):e12102. doi: 10.1097/MD.0000000000012102.

2.

Point: Does Chemoimmunotherapy Still Have a Role in CLL? Chemoimmunotherapy With FCR Is Still an Important Option in CLL.

Thompson PA, Tam CS.

Oncology (Williston Park). 2018 Jun;32(6):291-2, 294-6. No abstract available.

3.

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R.

Ann Hematol. 2018 Oct;97(10):1825-1839. doi: 10.1007/s00277-018-3380-z. Epub 2018 Jun 4. Erratum in: Ann Hematol. 2018 Jun 23;:.

4.

An ultrasonic nanobubble-mediated PNP/fludarabine suicide gene system: A new approach for the treatment of hepatocellular carcinoma.

Zhang B, Chen M, Zhang Y, Chen W, Zhang L, Chen L.

PLoS One. 2018 May 2;13(5):e0196686. doi: 10.1371/journal.pone.0196686. eCollection 2018.

5.

Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.

Abuelgasim KA, Rehan H, Alsubaie M, Al Atwi N, Al Balwi M, Alshieban S, Almughairi A.

J Med Case Rep. 2018 Mar 11;12(1):64. doi: 10.1186/s13256-018-1612-4. Review.

6.

A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups.

Ann Hematol. 2018 May;97(5):763-772. doi: 10.1007/s00277-018-3229-5. Epub 2018 Feb 2. Erratum in: Ann Hematol. 2018 Feb 23;:.

PMID:
29392425
7.

Coexistence of t(2;14;11)(p16.1;q32;q23) and t(14;19)(q32;q13.3) chromosome translocations in a patient with chronic lymphocytic leukemia: A case report.

Liu G, Wen Z, Lu X, Kim YM, Wang X, Crew RM, Cherry MA, Li S, Liu Y.

Medicine (Baltimore). 2017 Dec;96(51):e9169. doi: 10.1097/MD.0000000000009169.

8.

Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review.

Cencini E, Fabbri A, Lauria F, Bocchia M.

Ann Hematol. 2018 May;97(5):821-829. doi: 10.1007/s00277-018-3243-7. Epub 2018 Jan 16. Review.

PMID:
29340761
9.

[Outcomes of alternative donor allogeneic hematopoietic stem cell transplantation for Fanconi anemia: a five cases report].

Wang WJ, Sun YQ, Tang FF, Han TT, Mo XD, Wang JZ, Zhang XH, Huang XJ, Xu LP.

Zhonghua Nei Ke Za Zhi. 2018 Jan 1;57(1):54-56. doi: 10.3760/cma.j.issn.0578-1426.2018.01.010. Chinese.

PMID:
29325312
10.

The struggle to do no harm in clinical trials.

Schmidt C.

Nature. 2017 Dec 21;552(7685):S74-S75. doi: 10.1038/d41586-017-08705-4. No abstract available.

PMID:
29293235
11.

Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.

Scappaticci GB, Marini BL, Nachar VR, Uebel JR, Vulaj V, Crouch A, Bixby DL, Talpaz M, Perissinotti AJ.

Ann Hematol. 2018 Apr;97(4):573-584. doi: 10.1007/s00277-017-3217-1. Epub 2017 Dec 29.

PMID:
29288428
12.

Herpes, Simplex, Neonatorum.

Boyd RL, Kasman LM.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Feb 15.

13.

Analysis of factors affecting initial cyclosporine level and its impact on post transplant outcomes in acute leukemia.

Gupta A, Punatar S, Gawande J, Mathew L, Kannan S, Khattry N.

J Cancer Res Ther. 2017 Oct-Dec;13(6):981-988. doi: 10.4103/0973-1482.157338.

14.

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.

Gaidano G, Rossi D.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):329-337. doi: 10.1182/asheducation-2017.1.329. Review.

PMID:
29222275
15.

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.

Gocke CD, Gladstone DE.

Br J Haematol. 2018 Jan;180(1):7-8. doi: 10.1111/bjh.15015. Epub 2017 Dec 3. No abstract available.

PMID:
29205267
16.

[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Simon N, Coiteux V, Bruno B, Taque S, Charbonnier A, Souchet L, Vincent L, Yakoub-Agha I, Chalandon Y.

Bull Cancer. 2017 Dec;104(12S):S99-S105. doi: 10.1016/j.bulcan.2017.07.010. Epub 2017 Nov 23. Review. French.

PMID:
29173979
17.

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.

Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z.

Br J Haematol. 2018 Jan;180(1):33-40. doi: 10.1111/bjh.15018. Epub 2017 Nov 21.

PMID:
29164608
18.

Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy.

Kaya AH, Tekgündüz E, Ilkkiliç K, Dal MS, Merdin A, Karakus A, Hacioglu SK, Bekdemir F, Çakar MK, Dogu MH, Ayyildiz MO, Korkmaz S, Altuntaş F; On the behalf of The Turkish Hematology Research and Edication Group (ThREG).

J Chemother. 2018 Feb;30(1):44-48. doi: 10.1080/1120009X.2017.1396017. Epub 2017 Nov 3.

PMID:
29098953
19.

FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.

Chai-Adisaksopha C, Brown JR.

Blood. 2017 Nov 23;130(21):2278-2282. doi: 10.1182/blood-2017-07-731588. Epub 2017 Oct 12. Review.

PMID:
29025740
20.

Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault de Latour R, Marçais A, Bulabois CE, Bay JO, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-Agha I, Cornillon J, Mercier M, Turlure P, Charbonnier A, Rorhlich PS, N'Guyen S, Maillard N, Marchand T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Ann Oncol. 2017 Sep 1;28(9):2191-2198. doi: 10.1093/annonc/mdx274.

PMID:
28911060

Supplemental Content

Loading ...
Support Center